Robles A, Touriño R, Sesar A, Suárez P, Noya M
Servicio de Neurologia, Hospital Xeral de Galicia, Santiago de Compostela.
Rev Neurol. 1996 Jan;24(125):65-8.
Scinto et al (Science 1994; 266: 1051-4) observed that a single drop of 0.01% tropicamide elicited more than a 13% pupil dilatation in 19 individuals with probable or possible Alzheimer's disease (AD) and 3 cognitive abnormal elderly without dementia, but not in 30 out of 32 normal elderly and 3 out of 4 patients suffering from other dementias. It could be an easy and bloodless test to help in diagnosing AD. We have administered the same test to 10 patients with probable AD (NINCDS-ADRDA criteria) and twenty 40-90 year-old control subjects (10 of whom were sons or daughters of AD patients and 10 without a family history of dementia). The researcher does not know which group the subject belongs to. He administers a single drop of 0.01% tropicamide in eye and one drop of 0.45% normal saline solution in the other (without knowing the contents of either vial) and measures the pupil diameter by means of a Goldmann pupilometer in basal condition and 10, 15, 25, 30, 35, 45, and 55 minutes after. The results show that it is necessary to measure the pupils at least between the minutes 25 and 55 to detect tha maximum pupil dilation in every case. The cutoff point to consider the result positive must be located between 43 and 50%. If we establish the cutoff point in 50% of pupil dilation, 90% of AD patients and 35% of control subjects show a positive response. There was not a statistically significant difference between both control groups. Our results from this test show a sensitivity of 90% and a specificity of 65%. The positive responses of some control subjects may express a weak specificity, or perhaps they mean that we have a marker of the pre-clinical stage of the disease before us.
辛托等人(《科学》,1994年;266卷:1051 - 1054页)观察到,一滴0.01%的托吡卡胺能使19名可能患有或疑似患有阿尔茨海默病(AD)的个体以及3名认知异常但无痴呆的老年人的瞳孔扩张超过13%,但在32名正常老年人中的30名以及4名患有其他痴呆症的患者中的3名中却未出现这种情况。这可能是一种有助于诊断AD的简便且无创伤的检测方法。我们对10名符合可能的AD诊断标准(NINCDS - ADRDA标准)的患者以及20名40至90岁的对照受试者(其中10名是AD患者的子女,10名无痴呆家族史)进行了相同的检测。研究人员不知道受试者属于哪一组。他在一只眼睛中滴入一滴0.01%的托吡卡胺,在另一只眼睛中滴入一滴0.45%的生理盐水溶液(不知道两个小瓶中的内容物),并在基础状态以及之后的10、15、25、30、35、45和55分钟,使用戈德曼瞳孔计测量瞳孔直径。结果表明,为了在每种情况下检测到最大瞳孔扩张,至少需要在25至55分钟之间测量瞳孔。将结果判定为阳性的临界值必须设定在43%至50%之间。如果我们将瞳孔扩张的临界值设定为50%,90%的AD患者和35%的对照受试者会呈现阳性反应。两个对照组之间没有统计学上的显著差异。我们此次检测的结果显示敏感性为90%,特异性为65%。一些对照受试者的阳性反应可能表明特异性较弱,或者也许意味着我们面前有一种疾病临床前期的标志物。